OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
23
Results
Show all
Save search
Copy query
Show results for
Unknown
(23)
Publication Date
Release Date
2024
(7)
2022
(5)
2021
(4)
2025
(3)
2023
(2)
2020
(1)
2019
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
Not available
S-EPMC8284438
|
biostudies-literature
Cite
Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma.
Not available
S-EPMC8928100
|
biostudies-literature
Cite
Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer.
Not available
S-EPMC9754112
|
biostudies-literature
Cite
Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
Not available
S-EPMC6601540
|
biostudies-literature
Cite
A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
Not available
S-EPMC10801940
|
biostudies-literature
Cite
Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model.
Not available
S-EPMC9012943
|
biostudies-literature
Cite
Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Not available
S-EPMC10565143
|
biostudies-literature
Cite
Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants.
Not available
S-EPMC8843163
|
biostudies-literature
Cite
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors.
Not available
S-EPMC11443874
|
biostudies-literature
Cite
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.
Not available
S-EPMC11536336
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets